Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Carter HB, Costantino JP, Epstein JI, Godley PA, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P, American Society of Clinical Oncology/American Urological Association
J Urol. 2009 181 (4): 1642-57

PMID: 19249063 · DOI:10.1016/j.juro.2009.01.071

PURPOSE - To develop an evidence-based guideline on the use of 5-alpha-reductase inhibitors (5-ARIs) for prostate cancer chemoprevention.

METHODS - The American Society of Clinical Oncology (ASCO) Health Services Committee (HSC), ASCO Cancer Prevention Committee, and the American Urological Association Practice Guidelines Committee jointly convened a Panel of experts, who used the results from a systematic review of the literature to develop evidence-based recommendations on the use of 5-ARIs for prostate cancer chemoprevention.

RESULTS - The systematic review completed for this guideline identified 15 randomized clinical trials that met the inclusion criteria, nine of which reported prostate cancer period prevalence.

CONCLUSION - Asymptomatic men with a prostate-specific antigen (PSA)

MeSH Terms (5)

Chemoprevention Cholestenone 5 alpha-Reductase Humans Male Prostatic Neoplasms

Connections (1)

This publication is referenced by other Labnodes entities: